Guardant Health, Inc. - Common Stock (NQ:GH)

177.80 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

22 23 Next >

Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook ↗

November 07, 2023

Guardant Health Inc (NASDAQ: GH) reported Q3 revenue of $143 million, up 22% Y/Y, beating the consensus of $137.37 million

Via Benzinga

Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

November 06, 2023

From Guardant Health, Inc.

Via Business Wire

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Guardant Health to Participate in Upcoming November Investor Conferences

November 03, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform

October 31, 2023

From Guardant Health, Inc.

Via Business Wire

The Latest Analyst Ratings for Guardant Health ↗

October 20, 2023

Via Benzinga

Why Guardant Health Stock Popped Again Today ↗

September 28, 2023

Wall Street loves this unprofitable biotech.

Via The Motley Fool

Analyst Expectations for Guardant Health's Future ↗

September 27, 2023

Via Benzinga

Bull Of The Day: NeoGenomics ↗

October 24, 2023

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.

Via Talk Markets

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

October 23, 2023

From Guardant Health, Inc.

Via Business Wire

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

October 17, 2023

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

The Latest Analyst Ratings for Guardant Health ↗

August 04, 2023

Via Benzinga

Preview: Guardant Health's Earnings ↗

August 02, 2023

Via Benzinga

Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023

October 16, 2023

From Guardant Health, Inc.

Via Business Wire

1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years ↗

October 11, 2023

This company's fight against a deadly disease could pay off.

Via The Motley Fool

Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health? ↗

October 08, 2023

The oncology diagnostic companies are looking for better solutions in early cancer diagnosis.

Via The Motley Fool

Why Guardant Health Stock Jumped 15% This Week ↗

September 28, 2023

The precision oncology leader benefited from a pair of positive analyst notes this week. Here's what investors need to know.

Via The Motley Fool

Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst ↗

September 27, 2023

Shares of Guardant Health Inc (NASDAQ: GH) climbed during the premarket trading session and morning on Wednesday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗

September 28, 2023

Via Benzinga

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

September 26, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The...

Via FinancialNewsMedia

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗

September 27, 2023

Via Benzinga

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗

September 21, 2023

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Via Benzinga

Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan

September 06, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

September 05, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test

September 01, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 31, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Host Investor Day on September 7, 2023

August 17, 2023

From Guardant Health, Inc.

Via Business Wire

2 Cathie Wood Stocks to Buy and Hold for 10 Years ↗

August 10, 2023

These companies' growth stories still have plenty of exciting chapters ahead.

Via The Motley Fool

Guardant Health Stock Sees Renewed Technical Strength ↗

August 07, 2023

Guardant Health stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 79 to 85.

Via Investor's Business Daily

Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance

August 03, 2023

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.